Defeat Duchenne Canada is pleased to share the latest news from Dyne Therapeutics. Dyne Therapeutics is a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. Dyne has announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.

The Phase I/II trial hopes to enroll approximately 30 to 40 ambulant and non-ambulant male patients ages 4 to 16 with symptomatic DMD and mutations amenable to exon 51 skipping therapy by mid-2022. Defeat Duchenne Canada is pleased to support Dyne as they advance their DYNE-251 program into the clinic.

In addition to DYNE-251, Dyne is building a DMD franchise with programs for patients with mutations amenable to skipping exons 53, 45 and 44.

Click the button below to read the full press release.